Evidence map›Paper›PMID 39318627›Full record

ArticleFrontiers in immunology2024

Investigating pulmonary and non-infectious complications in common variable immunodeficiency disorders: a UK national multi-centre study.

Heba M Bintalib, Sofia Grigoriadou, Smita Y Patel, Leman Mutlu, Kavitha Sooriyakumar, Prashantha Vaitla, Elizabeth McDermott, Elizabeth Drewe, Cathal Steele, Manisha Ahuja and 9 more

Abstract readMulticenter Study
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Heba M BintalibUniversity College London (UCL) Respiratory, University College London, London, United Kingdom.
Sofia GrigoriadouDepartment of Immunology, Barts Health National Health Service (NHS) Trust, The Royal London Hospital, London, United Kingdom.
Smita Y PatelClinical Immunology, Oxford University Hospitals National Health Service (NHS) Foundation Trust, Oxford, United Kingdom.
Leman MutluClinical Immunology and Allergy, Department of Pathology, East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom.
Kavitha SooriyakumarDepartment of Allergy and Immunology, University Hospitals Birmingham National Health Service (NHS) Foundation Trust, Birmingham, United Kingdom.
Prashantha VaitlaClinical Immunology and Allergy Department, Queens Medical Centre campus, Nottingham University Hospitals National Health Service (NHS) Trust, Nottingham, United Kingdom.
Elizabeth McDermottClinical Immunology and Allergy Department, Queens Medical Centre campus, Nottingham University Hospitals National Health Service (NHS) Trust, Nottingham, United Kingdom.
Elizabeth DreweClinical Immunology and Allergy Department, Queens Medical Centre campus, Nottingham University Hospitals National Health Service (NHS) Trust, Nottingham, United Kingdom.
Cathal SteeleRegional Immunology Service of Northern Ireland, The Belfast Health and Social Care Trust, Belfast, United Kingdom.
Manisha AhujaClinical Research Fellow, Newcastle University; Specialist Registrar Newcastle upon Tyne Hospitals NHSFT, Newcastle, United Kingdom.
Tomaz GarcezDepartment of Immunology, Manchester University National Health Service (NHS) Foundation Trust, Manchester, United Kingdom.
Mark GompelsThe Bristol National Health Service (NHS) Immunology Allergy Centre, Southmead Hospital, North Bristol National Health Service (NHS) Trust, Bristol, United Kingdom.
Alexandros GrammatikosThe Bristol National Health Service (NHS) Immunology Allergy Centre, Southmead Hospital, North Bristol National Health Service (NHS) Trust, Bristol, United Kingdom.
Archana HerwadkarImmunology Department, Division of Surgery and Tertiary Medicine, Salford Royal National Health Service (NHS) Foundation Trust, Salford, United Kingdom.
Rehana AyubClinical Immunology, Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, United Kingdom.
Neil HallidayUniversity College London (UCL) Institute for Liver and Digestive Health, University College London, London, United Kingdom.
Siobhan O BurnsDepartment of Immunology, Royal Free London National Health Service (NHS) Foundation Trust, London, United Kingdom.
John R Hurst *University College London (UCL) Respiratory, University College London, London, United Kingdom.
Sarah Goddard *Department of Immunology, University Hospitals North Midlands, Royal Stoke Hospital, Stoke-on-Trent, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Common Variable Immunodeficiency Disorders (CVID) encompass a spectrum of immunodeficiency characterised by recurrent infections and diverse non-infectious complications (NICs). This study aimed to describe the clinical features and variation in NICs in CVID with and without interstitial lung disease (ILD) from a large UK national registry population. Methods: Retrospective, cross-sectional data from a UK multicentre database (previously known as UKPIN), categorising patients into those with CVID-ILD and those with NICs related to CVID but without pulmonary involvement (CVID-EP; EP= extra-pulmonary involvement only). Results: 129 patients were included. Chronic lung diseases, especially CVID-ILD, are prominent complications in complex CVID, occurring in 62% of the cohort. Bronchiectasis was common (64% of the cohort) and associated with greater pulmonary function impairment in patients with CVID-ILD compared to those without bronchiectasis. Lymphadenopathy and the absence of gastrointestinal diseases were significant predictors of ILD in complex CVID. Although the presence of liver disease did not differ significantly between the groups, nearly half of the CVID-ILD patients were found to have liver disease. Patients with CVID-ILD were more likely to receive immunosuppressive treatments such as rituximab and mycophenolate mofetil than the CVID-EP group, indicating greater need for treatment and risk of complications. Conclusion: This study highlights the significant burden of CVID-ILD within the CVID population with NICs only. The lungs emerged as the most frequently affected organ, with ILD and bronchiectasis both highly prevalent. These findings emphasise the necessity of a comprehensive and multidisciplinary approach in managing CVID patients, considering their susceptibility to various comorbidities and complications.

Indexed as

Common Variable ImmunodeficiencyLung Diseases, InterstitialAdultAgedBronchiectasisCross-Sectional StudiesFemaleHumansMaleMiddle AgedRegistriesRetrospective StudiesUnited KingdomYoung Adultbronchiectasiscommon variable immunodeficiencyGLILDinterstitial lung diseasenoninfectious complications

Identifiers

PMID39318627
PMCPMC11420000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.